Maintaining the balance: Costimulatory TNFRs and control of HIV

Cytokine and Growth Factor Reviews

Volumn 23, Issue 4-5, 2012, Pages 245-254

  Wang, Chao ^a   Watts, Tania H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

4 1BB; CD27; CD40; GITR; HIV; OX40; TNFR; TRAFs

Indexed keywords

ANTIRETROVIRUS AGENT; CD137 ANTIBODY; CD137 ANTIGEN; CD27 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD70 ANTIGEN; CYTOKINE ANTIBODY; CYTOKINE RECEPTOR AGONIST; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; LYMPHOTOXIN; LYMPHOTOXIN BETA RECEPTOR; NEF PROTEIN; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL LEVEL; CELL MATURATION; CELL SURFACE; COMBINATION CHEMOTHERAPY; DENDRITIC CELL; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; LATENT VIRUS INFECTION; LIGAND BINDING; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOCYTIC CHORIOMENINGITIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE ACTIVATION; VIRUS CELL INTERACTION; VIRUS IMMUNITY; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS TRANSMISSION;

HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; LYMPHOCYTE ACTIVATION; MODELS, IMMUNOLOGICAL; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PEPTIDES AND PROTEINS; VIRUS REPLICATION;

EID: 84864960776     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2012.05.011     Document Type: Article

References (135)

1. Moir S., Chun T.W., Fauci A.S. Pathogenic mechanisms of HIV disease. Annual Review of Pathology 2011, 6:223-248.
2. Cummins N.W., Badley A.D. Mechanisms of HIV-associated lymphocyte apoptosis: 2010. Cell Death Diseases 2010, 1:e99.
3. Fauci A.S. Host factors and the pathogenesis of HIV-induced disease. Nature 1996, 384:529-534.
4. Kobayashi N., Hamamoto Y., Yamamoto N. Is TNF involved in the progression of AIDS?. Virus Genes 1990, 4:183-190.
5. Poli G., Fauci A.S. The effect of cytokines and pharmacologic agents on chronic HIV infection. AIDS Research and Human Retroviruses 1992, 8:191-197.
6. Cepeda E.J., Williams F.M., Ishimori M.L., Weisman M.H., Reveille J.D. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Annals of the Rheumatic Diseases 2008, 67:710-712.
7. Calabrese L.H., Zein N., Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Annals of the Rheumatic Diseases 2004, 63(Suppl. 2):ii18-ii24.
8. Elgueta R., Benson M.J., de Vries V.C., Wasiuk A., Guo Y., Noelle R.J. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunological Reviews 2009, 229:152-172.
9. Bennett S.R., Carbone F.R., Karamalis F., Flavell R.A., Miller J.F., Heath W.R. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998, 393:478-480.
10. Ridge J.P., Di Rosa F., Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998, 393:474-478.
11. Schoenberger S.P., Toes R.E., van der Voort E.I., Offringa R., Melief C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998, 393:480-483.
12. Kornbluth R.S. An expanding role for CD40L and other tumor necrosis factor superfamily ligands in HIV infection. Journal of Hematotherapy & Stem Cell Research 2002, 11:787-801.
13. Pido-Lopez J., Whittall T., Wang Y., Bergmeier L.A., Babaahmady K., Singh M., et al. Stimulation of cell surface CCR5 and CD40 molecules by their ligands or by HSP70 up-regulates APOBEC3G expression in CD4(+) T cells and dendritic cells. Journal of Immunology 2007, 178:1671-1679.
14. Bergamini A., Bolacchi F., Pesce C.D., Carbone M., Cepparulo M., Demin F., et al. Increased CD4 and CCR5 expression and human immunodeficiency virus type 1 entry in CD40 ligand-stimulated macrophages. The Journal of Infectious Diseases 2002, 185:1567-1577.
15. Bakri Y., Mannioui A., Ylisastigui L., Sanchez F., Gluckman J.C., Benjouad A. CD40-activated macrophages become highly susceptible to X4 strains of human immunodeficiency virus type 1. AIDS Research and Human Retroviruses 2002, 18:103-113.
16. Connor R.I., Sheridan K.E., Ceradini D., Choe S., Landau N.R. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. The Journal of Experimental Medicine 1997, 185:621-628.
17. Sui Z., Sniderhan L.F., Schifitto G., Phipps R.P., Gelbard H.A., Dewhurst S., et al. Functional synergy between CD40 ligand and HIV-1 Tat contributes to inflammation: implications in HIV type 1 dementia. Journal of Immunology 2007, 178:3226-3236.
18. D'Aversa T.G., Eugenin E.A., Berman J.W. NeuroAIDS: contributions of the human immunodeficiency virus-1 proteins Tat and gp120 as well as CD40 to microglial activation. Journal of Neuroscience Research 2005, 81:436-446.
19. Sipsas N.V., Sfikakis P.P., Kontos A., Kordossis T. Levels of soluble CD40 ligand (CD154) in serum are increased in human immunodeficiency virus type 1-infected patients and correlate with CD4(+) T-cell counts. Clinical and Diagnostic Laboratory Immunology 2002, 9:558-561.
20. Moir S., Fauci A.S. B cells in HIV infection and disease. Nature Reviews Immunology 2009, 9:235-245.
21. Martin G., Tremblay M.J. HLA-DR, ICAM-1, CD40, CD40L, and CD86 are incorporated to a similar degree into clinical human immunodeficiency virus type 1 variants expanded in natural reservoirs such as peripheral blood mononuclear cells and human lymphoid tissue cultured ex vivo. Clinical Immunology 2004, 111:275-285.
22. Imbeault M., Ouellet M., Giguere K., Bertin J., Belanger D., Martin G., et al. Acquisition of host-derived CD40L by HIV-1 in vivo and its functional consequences in the B-cell compartment. Journal of Virology 2011, 85:2189-2200.
23. Epeldegui M., Thapa D.R., De la Cruz J., Kitchen S., Zack J.A., Martinez-Maza O. CD40 ligand (CD154) incorporated into HIV virions induces activation-induced cytidine deaminase (AID) expression in human B lymphocytes. PLoS One 2010, 5:e11448.
24. Qiao X., He B., Chiu A., Knowles D.M., Chadburn A., Cerutti A. Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nature Immunology 2006, 7:302-310.
25. Banchereau J., Bazan F., Blanchard D., Briere F., Galizzi J.P., van Kooten C., et al. The CD40 antigen and its ligand. Annual Review of Immunology 1994, 12:881-922.
26. Chougnet C. Role of CD40 ligand dysregulation in HIV-associated dysfunction of antigen-presenting cells. Journal of Leukocyte Biology 2003, 74:702-709.
27. Zhang R., Fichtenbaum C.J., Hildeman D.A., Lifson J.D., Chougnet C. CD40 ligand dysregulation in HIV infection: HIV glycoprotein 120 inhibits signaling cascades upstream of CD40 ligand transcription. Journal of Immunology 2004, 172:2678-2686.
28. Subauste C.S., Subauste A., Wessendarp M. Role of CD40-dependent down-regulation of CD154 in impaired induction of CD154 in CD4(+) T cells from HIV-1-infected patients. Journal of Immunology 2007, 178:1645-1653.
29. Ostrowski M.A., Justement S.J., Ehler L., Mizell S.B., Lui S., Mican J., et al. The role of CD4+ T cell help and CD40 ligand in the in vitro expansion of HIV-1-specific memory cytotoxic CD8+ T cell responses. Journal of Immunology 2000, 165:6133-6141.
30. Zhang R., Lifson J.D., Chougnet C. Failure of HIV-exposed CD4+ T cells to activate dendritic cells is reversed by restoration of CD40/CD154 interactions. Blood 2006, 107:1989-1995.
31. Yu Q., Gu J.X., Kovacs C., Freedman J., Thomas E.K., Ostrowski M.A. Cooperation of TNF family members CD40 ligand, receptor activator of NF-kappa B ligand, and TNF-alpha in the activation of dendritic cells and the expansion of viral specific CD8+ T cell memory responses in HIV-1-infected and HIV-1-uninfected individuals. Journal of Immunology 2003, 170:1797-1805.
32. Liu J., Yu Q., Stone G.W., Yue F.Y., Ngai N., Jones R.B., et al. CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals. Vaccine 2008, 26:4062-4072.
33. De Keersmaecker B., Heirman C., Corthals J., Empsen C., van Grunsven L.A., Allard S.D., et al. The combination of 4-1BBL and CD40L strongly enhances the capacity of dendritic cells to stimulate HIV-specific T cell responses. Journal of Leukocyte Biology 2011, 89:989-999.
34. Zheng M., Ramsay A.J., Robichaux M.B., Norris K.A., Kliment C., Crowe C., et al. CD4+ T cell-independent DNA vaccination against opportunistic infections. The Journal of Clinical Investigation 2005, 115:3536-3544.
35. Gommerman J.L., Browning J.L. Lymphotoxin/light, lymphoid microenvironments and autoimmune disease. Nature Reviews Immunology 2003, 3:642-655.
36. Summers Deluca L., Ng D., Gao Y., Wortzman M.E., Watts T.H., Gommerman J.L. LT{beta}R signaling in dendritic cells induces a type I IFN response that is required for optimal clonal expansion of CD8+ T cells. Proceedings of the National Academy of Sciences of the United States of America 2011.
37. Summers-DeLuca L.E., McCarthy D.D., Cosovic B., Ward L.A., Lo C.C., Scheu S., et al. Expression of lymphotoxin-alphabeta on antigen-specific T cells is required for DC function. Journal of Experimental Medicine 2007, 204:1071-1081.
38. Gommerman J.L., Summers deLuca L. LTbetaR and CD40: working together in dendritic cells to optimize immune responses. Immunological Reviews 2011, 244:85-98.
39. Marshall W.L., Brinkman B.M., Ambrose C.M., Pesavento P.A., Uglialoro A.M., Teng E., et al. Signaling through the lymphotoxin-beta receptor stimulates HIV-1 replication alone and in cooperation with soluble or membrane-bound TNF-alpha. Journal of Immunology 1999, 162:6016-6023.
40. Watts T.H. TNF/TNFR family members in costimulation of T cell responses. Annual Review of Immunology 2005, 23:23-68.
41. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?. Nature Reviews Immunology 2003, 3:609-620.
42. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nature Reviews Immunology 2009, 9:271-285.
43. Niu L., Strahotin S., Hewes B., Zhang B., Zhang Y., Archer D., et al. Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. Journal of Immunology 2007, 178:4194-4213.
44. Arens R., Tesselaar K., Baars P.A., van Schijndel G.M., Hendriks J., Pals S.T., et al. Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNgamma-mediated B cell depletion. Immunity 2001, 15:801-812.
45. Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:682-687.
46. Brooks D.G., Walsh K.B., Elsaesser H., Oldstone M.B. IL-10 directly suppresses CD4 but not CD8 T cell effector and memory responses following acute viral infection. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:3018-3023.
47. Day C.L., Kaufmann D.E., Kiepiela P., Brown J.A., Moodley E.S., Reddy S., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354.
48. Freeman G.J., Wherry E.J., Ahmed R., Sharpe A.H. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. Journal of Experimental Medicine 2006, 203:2223-2227.
49. Jin H.T., Anderson A.C., Tan W.G., West E.E., Ha S.J., Araki K., et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:14733-14738.
50. Jones R.B., Ndhlovu L.C., Barbour J.D., Sheth P.M., Jha A.R., Long B.R., et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. Journal of Experimental Medicine 2008, 205:2763-2779.
51. Petrovas C., Casazza J.P., Brenchley J.M., Price D.A., Gostick E., Adams W.C., et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. Journal of Experimental Medicine 2006, 203:2281-2292.
52. Tinoco R., Alcalde V., Yang Y., Sauer K., Zuniga E.I. Cell-intrinsic transforming growth factor-beta signaling mediates virus-specific CD8+ T cell deletion and viral persistence in vivo. Immunity 2009, 31:145-157.
53. Trautmann L., Janbazian L., Chomont N., Said E.A., Wang G., Gimmig S., et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nature Medicine 2006, 12:1198-1202.
54. Urbani S., Amadei B., Tola D., Massari M., Schivazappa S., Missale G., et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. Journal of Virology 2006, 80:11398-11403.
55. Wang C., McPherson A.J., Jones R.B., Kawamura K.S., Lin G.H., Lang P.A., et al. Loss of the signaling adaptor TRAF1 causes CD8+ T cell dysregulation during human and murine chronic infection. The Journal of Experimental Medicine 2012, 209:77-91.
56. Nolte M.A., van Olffen R.W., van Gisbergen K.P., van Lier R.A. Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunological Reviews 2009, 229:216-231.
57. Denoeud J., Moser M. Role of CD27/CD70 pathway of activation in immunity and tolerance. Journal of Leukocyte Biology 2011, 89:195-203.
58. De Milito A., Aleman S., Marenzi R., Sonnerborg A., Fuchs D., Zazzi M., et al. Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-1-infected subjects. Clinical and Experimental Immunology 2002, 127:486-494.
59. Hamann D., Baars P.A., Rep M.H., Hooibrink B., Kerkhof-Garde S.R., Klein M.R., et al. Phenotypic and functional separation of memory and effector human CD8+ T cells. Journal of Experimental Medicine 1997, 186:1407-1418.
60. Dang L.V., Nilsson A., Ingelman-Sundberg H., Cagigi A., Gelinck L.B., Titanji K., et al. Soluble CD27 induces IgG production through activation of antigen-primed B cells. Journal of Internal Medicine 2012, 271:282-293.
61. Beishuizen C.R., Kragten N.A., Boon L., Nolte M.A., van Lier R.A., van Gisbergen K.P. Chronic CD70-driven costimulation impairs IgG responses by instructing T cells to inhibit germinal center B cell formation through FasL-Fas interactions. Journal of Immunology 2009, 183:6442-6451.
62. Tesselaar K., Arens R., van Schijndel G.M., Baars P.A., van der Valk M.A., Borst J., et al. Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions. Nature Immunology 2003, 4:49-54.
63. Widney D., Gundapp G., Said J.W., van der Meijden M., Bonavida B., Demidem A., et al. Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. Clinical Immunology 1999, 93:114-123.
64. Peruchon S., Chaoul N., Burelout C., Delache B., Brochard P., Laurent P., et al. Tissue-specific B-cell dysfunction and generalized memory B-cell loss during acute SIV infection. PLoS One 2009, 4:e5966.
65. Wolthers K.C., Otto S.A., Lens S.M., Van Lier R.A., Miedema F., Meyaard L. Functional B cell abnormalities in HIV type 1 infection: role of CD40L and CD70. AIDS Research and Human Retroviruses 1997, 13:1023-1029.
66. De Milito A., Morch C., Sonnerborg A., Chiodi F. Loss of memory (CD27) B lymphocytes in HIV-1 infection. AIDS 2001, 15:957-964.
67. Wolthers K.C., Otto S.A., Lens S.M., Kolbach D.N., van Lier R.A., Miedema F., et al. Increased expression of CD80, CD86 and CD70 on T cells from HIV-infected individuals upon activation in vitro: regulation by CD4+ T cells. European Journal of Immunology 1996, 26:1700-1706.
68. Appay V., Dunbar P.R., Callan M., Klenerman P., Gillespie G.M., Papagno L., et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nature Medicine 2002, 8:379-385.
69. Appay V., Nixon D.F., Donahoe S.M., Gillespie G.M., Dong T., King A., et al. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. Journal of Experimental Medicine 2000, 192:63-75.
70. van Baarle D., Kostense S., van Oers M.H., Hamann D., Miedema F. Failing immune control as a result of impaired CD8+ T-cell maturation: CD27 might provide a clue. Trends in Immunology 2002, 23:586-591.
71. Zhang D., Shankar P., Xu Z., Harnisch B., Chen G., Lange C., et al. Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. Blood 2003, 101:226-235.
72. Ochsenbein A.F., Riddell S.R., Brown M., Corey L., Baerlocher G.M., Lansdorp P.M., et al. CD27 expression promotes long-term survival of functional effector-memory CD8+ cytotoxic T lymphocytes in HIV-infected patients. Journal of Experimental Medicine 2004, 200:1407-1417.
73. Killian M.S., Johnson C., Teque F., Fujimura S., Levy J.A. Natural suppression of human immunodeficiency virus type 1 replication is mediated by transitional memory CD8+ T cells. Journal of Virology 2011, 85:1696-1705.
74. Hendriks J., Xiao Y., Borst J. CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool. Journal of Experimental Medicine 2003, 198:1369-1380.
75. Taraban V.Y., Rowley T.F., Al-Shamkhani A. Cutting edge: a critical role for CD70 in CD8 T cell priming by CD40-licensed APCs. Journal of Immunology 2004, 173:6542-6546.
76. Wang C., Wen T., Routy J.P., Bernard N.F., Sekaly R.P., Watts T.H. 4-1BBL induces TNF receptor-associated factor 1-dependent Bim modulation in human T cells and is a critical component in the costimulation-dependent rescue of functionally impaired HIV-specific CD8 T cells. Journal of Immunology 2007, 179:8252-8263.
77. Snell L.M., Lin G.H., McPherson A.J., Moraes T.J., Watts T.H. T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy. Immunological Reviews 2011, 244:197-217.
78. Wang C., Lin G.H., McPherson A.J., Watts T.H. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunological Reviews 2009, 229:192-215.
79. Lin G.H., Sedgmen B.J., Moraes T.J., Snell L.M., Topham D.J., Watts T.H. Endogenous 4-1BB ligand plays a critical role in protection from influenza-induced disease. Journal of Immunology 2009, 182:934-947.
80. Arch R.H., Thompson C.B. 4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor κB. Molecular and Cellular Biology 1998, 18:558-565.
81. Jang I.K., Lee Z.H., Kim Y.J., Kim S.H., Kwon B.S. Human 4-1BB (CD137) signals are mediated by TRAF2 and activate nuclear factor-kappa B. Biochemical and Biophysical Research Communications 1998, 242:613-620.
82. Saoulli K., Lee S.Y., Cannons J.L., Yeh W.C., Santana A., Goldstein M.D., et al. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. Journal of Experimental Medicine 1998, 187:1849-1862.
83. Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nature Reviews Immunology 2003, 3:745-756.
84. Lee S.Y., Choi Y. TRAF1 and its biological functions. Advances in Experimental Medicine and Biology 2007, 597:25-31.
85. Arron J.R., Pewzner-Jung Y., Walsh M.C., Kobayashi T., Choi Y. Regulation of the subcellular localization of tumor necrosis factor receptor-associated factor (TRAF)2 by TRAF1 reveals mechanisms of TRAF2 signaling. Journal of Experimental Medicine 2002, 196:923-934.
86. Xie P., Hostager B.S., Munroe M.E., Moore C.R., Bishop G.A. Cooperation between TNF receptor-associated factors 1 and 2 in CD40 signaling. Journal of Immunology 2006, 176:5388-5400.
87. Speiser D.E., Lee S.Y., Wong B., Arron J., Santana A., Kong Y.Y., et al. A regulatory role for TRAF1 in antigen-induced apoptosis of T cells. Journal of Experimental Medicine 1997, 185:1777-1783.
88. Sabbagh L., Srokowski C.C., Pulle G., Snell L.M., Sedgmen B.J., Liu Y., et al. A critical role for TNF receptor-associated factor 1 and Bim down-regulation in CD8 memory T cell survival. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:18703-18708.
89. Sabbagh L., Pulle G., Liu Y., Tsitsikov E.N., Watts T.H. ERK-dependent bim modulation downstream of the 4-1BB-TRAF1 signaling axis is a critical mediator of CD8 T cell survival in vivo. Journal of Immunology 2008, 180:8093-8101.
90. Rothe M., Wong S.C., Henzel W.J., Goeddel D.V. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75kDa tumor necrosis factor receptor. Cell 1994, 78:681-692.
91. Zheng C., Kabaleeswaran V., Wang Y., Cheng G., Wu H. Crystal structures of the TRAF2: cIAP2 and the TRAF1: TRAF2: cIAP2 complexes: affinity, specificity, and regulation. Molecular Cell 2010, 38:101-113.
92. Kassu A., D'Souza M., O'Connor B.P., Kelly-McKnight E., Akkina R., Fontenot A.P., et al. Decreased 4-1BB expression on HIV-specific CD4+ T cells is associated with sustained viral replication and reduced IL-2 production. Clinical Immunology 2009, 132:234-245.
93. Zapata J.M., Krajewska M., Krajewski S., Kitada S., Welsh K., Monks A., et al. TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. Journal of Immunology 2000, 165:5084-5096.
94. Wang X., Wang Q., Hu W., Evers B.M. Regulation of phorbol ester-mediated TRAF1 induction in human colon cancer cells through a PKC/RAF/ERK/NF-kappaB-dependent pathway. Oncogene 2004, 23:1885-1895.
95. Cerhan J.R., Ansell S.M., Fredericksen Z.S., Kay N.E., Liebow M., Call T.G., et al. Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood 2007, 110:4455-4463.
96. Albers H.M., Kurreeman F.A., Houwing-Duistermaat J.J., Brinkman D.M., Kamphuis S.S., Girschick H.J., et al. The TRAF1/C5 region is a risk factor for polyarthritis in juvenile idiopathic arthritis. Annals of the Rheumatic Diseases 2008, 67:1578-1580.
97. Behrens E.M., Finkel T.H., Bradfield J.P., Kim C.E., Linton L., Casalunovo T., et al. Association of the TRAF1-C5 locus on chromosome 9 with juvenile idiopathic arthritis. Arthritis and Rheumatism 2008, 58:2206-2207.
98. Kurreeman F.A., Padyukov L., Marques R.B., Schrodi S.J., Seddighzadeh M., Stoeken-Rijsbergen G., et al. A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis. PLoS Medicine 2007, 4:e278.
99. Plenge R.M., Seielstad M., Padyukov L., Lee A.T., Remmers E.F., Ding B., et al. TRAF1-C5 as a risk locus for rheumatoid arthritis - a genomewide study. New England Journal of Medicine 2007, 357:1199-1209.
100. Bukczynski J., Wen T., Wang C., Christie N., Routy J.P., Boulassel M.R., et al. Enhancement of HIV-specific CD8 T cell responses by dual costimulation with CD80 and CD137L. Journal of Immunology 2005, 175:6378-6389.
101. Levy Y., Lacabaratz C., Weiss L., Viard J.P., Goujard C., Lelievre J.D., et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. Journal of Clinical Investigation 2009, 119:997-1007.
102. Ascierto P.A., Simeone E., Sznol M., Fu Y.X., Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Seminars in Oncology 2010, 37:508-516.
103. Vezys V., Penaloza-MacMaster P., Barber D.L., Ha S.J., Konieczny B., Freeman G.J., et al. 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection. Journal of Immunology 2011, 187:1634-1642.
104. Serghides L., Bukczynski J., Wen T., Wang C., Routy J.P., Boulassel M.R., et al. Evaluation of OX40 ligand as a costimulator of human antiviral memory CD8 T cell responses: comparison with B7.1 and 4-1BBL. Journal of Immunology 2005, 175:6368-6377.
105. Yu Q., Yue F.Y., Gu X.X., Schwartz H., Kovacs C.M., Ostrowski M.A. OX40 ligation of CD4+ T cells enhances virus-specific CD8+ T cell memory responses independently of IL-2 and CD4+ T regulatory cell inhibition. Journal of Immunology 2006, 176:2486-2495.
106. Ahlers J.D., Belyakov I.M., Terabe M., Koka R., Donaldson D.D., Thomas E.K., et al. A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:13020-13025.
107. Lahey T.P., Loisel S.D., Wieland-Alter W. Glucocorticoid-induced tumor necrosis factor receptor family-related protein triggering enhances HIV-specific CD4+ T cell cytokine secretion and protects HIV-specific CD4+ T cells from apoptosis. The Journal of Infectious Diseases 2007, 196:43-49.
108. Snell L.M., McPherson A.J., Lin G.H., Sakaguchi S., Pandolfi P.P., Riccardi C., et al. CD8 T cell-intrinsic GITR is required for T cell clonal expansion and mouse survival following severe influenza infection. Journal of Immunology 2010, 185:7223-7234.
109. Dittmer U., Werner T., Kraft A.R. Co-immunization of mice with a retroviral DNA vaccine and GITRL-encoding plasmid augments vaccine-induced protection against retrovirus infection. Viral Immunology 2008, 21:459-467.
110. Lee S.W., Salek-Ardakani S., Mittler R.S., Croft M. Hypercostimulation through 4-1BB distorts homeostasis of immune cells. Journal of Immunology 2009, 182:6753-6762.
111. Wang S., Kim Y.J., Bick C., Kim S.H., Kwon B.S. The potential roles of 4-1BB costimulation in HIV type 1 infection. AIDS Research and Human Retroviruses 1998, 14:223-231.
112. Harrison J.M., Bertram E.M., Boyle D.B., Coupar B.E., Ranasinghe C., Ramshaw I.A. 4-1BBL coexpression enhances HIV-specific CD8 T cell memory in a poxvirus prime-boost vaccine. Vaccine 2006, 24:6867-6874.
113. Kanagavelu S.K., Snarsky V., Termini J.M., Gupta S., Barzee S., Wright J.A., et al. Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine. Vaccine 2012, 30:691-702.
114. Moraes T.J., Lin G.H., Wen T., Watts T.H. Incorporation of 4-1BB ligand into an adenovirus vaccine vector increases the number of functional antigen-specific CD8 T cells and enhances the duration of protection against influenza-induced respiratory disease. Vaccine 2011, 29:6301-6312.
115. Pellegrini M., Calzascia T., Toe J.G., Preston S.P., Lin A.E., Elford A.R., et al. IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell 2011, 144:601-613.
116. Kalos M., Levine B.L., Porter D.L., Katz S., Grupp S.A., Bagg A., et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Science Translational Medicine 2011, 3. 95ra73.
117. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. The New England Journal of Medicine 2011, 365:725-733.
118. Milone M.C., Fish J.D., Carpenito C., Carroll R.G., Binder G.K., Teachey D., et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Molecular Therapy 2009, 17:1453-1464.
119. Ertl H.C., Zaia J., Rosenberg S.A., June C.H., Dotti G., Kahn J., et al. Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010. Cancer Research 2011, 71:3175-3181.
120. Chun T.W., Carruth L., Finzi D., Shen X., DiGiuseppe J.A., Taylor H., et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387:183-188.
121. Chun T.W., Fauci A.S. Latent reservoirs of HIV: obstacles to the eradication of virus. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:10958-10961.
122. Chomont N., El-Far M., Ancuta P., Trautmann L., Procopio F.A., Yassine-Diab B., et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nature Medicine 2009, 15:893-900.
123. Chun T.W., Davey R.T., Ostrowski M., Shawn Justement J., Engel D., Mullins J.I., et al. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nature Medicine 2000, 6:757-761.
124. Bailey J.R., Sedaghat A.R., Kieffer T., Brennan T., Lee P.K., Wind-Rotolo M., et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. Journal of Virology 2006, 80:6441-6457.
125. Brennan T.P., Woods J.O., Sedaghat A.R., Siliciano J.D., Siliciano R.F., Wilke C.O. Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. Journal of Virology 2009, 83:8470-8481.
126. Duverger A., Jones J., May J., Bibollet-Ruche F., Wagner F.A., Cron R.Q., et al. Determinants of the establishment of human immunodeficiency virus type 1 latency. Journal of Virology 2009, 83:3078-3093.
127. Chan J.K., Greene W.C. NF-kappaB/Rel: agonist and antagonist roles in HIV-1 latency. Current Opinion in HIV and AIDS 2011, 6:12-18.
128. Withers D.R., Jaensson E., Gaspal F., McConnell F.M., Eksteen B., Anderson G., et al. The survival of memory CD4+ T cells within the gut lamina propria requires OX40 and CD30 signals. Journal of Immunology 2009, 183:5079-5084.
129. Chun T.W., Engel D., Mizell S.B., Ehler L.A., Fauci A.S. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. The Journal of Experimental Medicine 1998, 188:83-91.
130. Burnett J.C., Lim K.I., Calafi A., Rossi J.J., Schaffer D.V., Arkin A.P. Combinatorial latency reactivation for HIV-1 subtypes and variants. Journal of Virology 2010, 84:5958-5974.
131. Wolschendorf F., Bosque A., Shishido T., Duverger A., Jones J., Planelles V., et al. Kinase control prevents HIV-1 reactivation in spite of high levels of induced NF-kappaB activity. Journal of Virology 2012, 86:4548-4558.
132. Cannons J.L., Hoeflich K.P., Woodgett J.R., Watts T.H. Role of the stress kinase pathway in signaling via the T cell costimulatory receptor 4-1BB. Journal of Immunology 1999, 163:2990-2998.
133. Yeh W.C., Shahinian A., Speiser D., Kraunus J., Billia F., Wakeham A., et al. Early lethality, functional NF-κB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity 1997, 7:715-725.
134. Pantaleo G., Graziosi C., Fauci A.S. New concepts in the immunopathogenesis of human immunodeficiency virus infection. The New England Journal of Medicine 1993, 328:327-335.
135. Pollok K.E., Kim Y.-J., Zhou Z., Hurtado J., Kim K.K., Pickard R.T., et al. Inducible T cell antigen 4-1BB: analysis of expression and function. Journal of Immunology 1993, 150:771-781.